Zoetis Inc. logo

Zoetis Inc.

ZTS | NYSE
Chart Builder DCF Calculator
$82.11
-$7.09 (-7.95%)
At close: Nov 5, 2026, 4:00 PM ET
$81.75
-$0.36 (-0.44%)
After-hours: Nov 5, 2026, 5:10 PM ET

Company Profile

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Key Executives

Name Position
Kristin C. Peck Chief Executive Officer & Director
Wetteny N. Joseph Special Advisor to the CEO
Abhay U. Nayak Executive VP & President of U.S. Commercial Operations
James K. Saccaro Executive VP, CFO & COO
Jamie Brannan Executive Vice President & Chief Commercial Officer
Jeannette Ferran Astorga Executive Vice President of Corporate Affairs & Chief Sustainability Officer
Julie A. Fuller Executive Vice President, Chief Human Resources Officer & Global Operations
Keith Sarbaugh Executive Vice President & Chief Digital and Technology Officer
Nick Ashton Executive Vice President and President of Global Manufacturing & Supply
Robert J. Polzer Scientific Advisor
Roxanne Lagano Executive Vice President, General Counsel & Corporate Secretary
Steven Frank Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 02, 2026 4 Filing
Aug 24, 2026 3 Filing
Aug 11, 2026 4 Filing
Aug 06, 2026 8-K Current Report
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Jul 30, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 14, 2026 4 Filing
View All SEC Filings ➞
Zoetis Inc.
Zoetis Inc. logo
Country United States
IPO Date Feb 1, 2013
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 14,500
CEO Kristin C. Peck

Contact Details

10 Sylvan Way Parsippany, New Jersey 07054 United States

Stock Details

Ticker Symbol ZTS
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001555280
CUSIP Number 98978V103
ISIN Number US98978V1035
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.